Cicada swarm is here!

Thank you silke gillessen and aurelius omlin for a magnificent Advanced Prostate Cancer Consensus Conference with friends and colleagues from around the world! DCI Center for Prostate & Urologic Cancers PCF Science

New evidence-based PCF Prostate Cancer Screening Guidelines for Black Men in the U.S. recommend that Black men consider PSA screening between ages 40-45, and screen annually depending on PSA levels and health status. 🧵⬇️

NEPC (Neuroendocrine PC) vs AVPC (Agressive Variants of PC) by Andrew Armstrong in Advanced Prostate Cancer Consensus Conference 2024
OncoAlert UroToday.com CLOC: Curso Latinoamericano de Oncología Clínica Urooncologia.arg

Fantastic insights from Andrew Armstrong How to treat men with aggressive variant or neuroendocrine prostate cancer?
⭕️ No level 1 evidence
⭕️ AVPC clinical criteria do not always align with genomics nor histology
⭕️ Platinum based chemotherapy recommended in most guidelines…

Enjoying controversial topics in sunny Lugano! Just a few cowbells but lots of impactful discussion! silke gillessen Advanced Prostate Cancer Consensus Conference DCI Center for Prostate & Urologic Cancers

Tune in Sunday 4/21 at 3 pm ET to WUNC and NPR radio for our People’s Pharmacy discussion of prostate cancer ! With Bridget Koontz DCI Center for Prostate & Urologic Cancers. Prostate Cancer Promise highlighted! peoplespharmacy.com/articles/show-…

Looking forward to this Saturday! peoplespharmacy.com/articles/show-… DCI Center for Prostate & Urologic Cancers

ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team…

Additional safety data updated from PROPEL just out in European Urology Oncology sciencedirect.com/science/articl…
DCI Center for Prostate & Urologic Cancers

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations | JCO Precision Oncology ascopubs.org/doi/10.1200/PO… nice work PROMISE team! Joe Park and DCI Center for Prostate & Urologic Cancers University of Michigan

TDXD received FDA accelerated approval in HER2 IHC 3+ treatment refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing needed. This seems an ambitious accelerated approval in UC #EAU24 . fda.gov/drugs/resource…

Why rush radiotherapy after prostate surgery?
☢️RADICALS-RT trial shows waiting for PSA rise before radiotherapy could be the smarter move – fewer side effects without compromising cancer control. A potential game-changer for post-surgery treatment. #ProstateCancer
Matt Sydes…

Honored be part of this amazing DCI Center for Prostate & Urologic Cancers 2023 Challenge team with Jiaoti Huang, Susan Halabi, Michael Zalutsky, and Kent Weinhold to develop new NEPC therapeutics!

Just published! Efficacy of PARP Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: FDA Pooled Analysis - Journal of Clinical Oncology. Jaleh Fallah, Daniel Suzman.
ascopubs.org/doi/pdf/10.120…

#OCEPublications

We're excited to announce the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research. 💙

bit.ly/3TyvCPl

🔬 #APCCC24 's Session 7 invites you to delve into the genetic landscape of advanced prostate cancer.

Chairs Himisha Beltran Misha Beltran and Andrew Armstrong Andrew Armstrong lead an esteemed panel, including Heather Cheng Heather H. Cheng and Ana Aparicio Ana Aparicio, to discuss…

That’s a wrap! Thanks Alan H Bryce and #USProstateCancerConference OncLive.com for a great consensus meeting on the gray areas advanced prostate cancer patient management. DCI Center for Prostate & Urologic Cancers

Lots of #prostatecancer brain power here in NYC! Amazing colleagues here — kudos to Alan H Bryce Phillip Koo, MD David Crawford, MD for bringing us all together
Andrew Armstrong Misha Beltran Tanya Dorff Emmanuel Antonarakis Prostate Cancer Foundation

What if you could change the lives of patients w/ #ProstateCancer ?

Gain expert insights from Andrew Armstrong, Matt Labriola, Dr. Fecteau, Hannah Dzimitrowicz McManus via our CME/CNE Medical Podcast!

Listen now: ow.ly/v9x850QGQO2

#medicalpodcast #oncology